Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab Dose Escalation in Severe Asthma
NCT04710134Phase 4Completed
- Sponsor
- McMaster University
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of reslizumab in eosinophilic asthma (EA), sponsored by McMaster University. Started Feb 2021; status: completed.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04710134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710134.